Latest Research And Development News

Page 8 of 115
archTIS has reached a significant cash conversion milestone, with quarterly customer receipts exceeding operating payments for the first time since its Spirion acquisition. The cybersecurity company also reported higher margins, lower costs and fresh U.S. defence work, although its most closely watched enterprise licence remains unsigned.
Victor Sage
Victor Sage
28 Oct 2026
Audeara has moved two AI noise reduction licensing programs into commercial production, helping lift quarterly revenue 37.7% while initial orders remain modest. The milestone arrives alongside A$247,000 in cash, a A$1.292 million operating outflow and a pending A$505,000 placement tranche.
Victor Sage
Victor Sage
28 Oct 2026
Sea Forest lifted first-quarter revenue 67% to A$3.4 million and generated a small operating cash inflow as it transitioned to a new distribution arrangement with Teys Australia. The agreement carries an indicative target of 480,000 cattle by June 2027, but the volume is not guaranteed and remains subject to implementation conditions.
Victor Sage
Victor Sage
28 Oct 2026
LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.
Victor Sage
Victor Sage
28 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
Norwood Systems reported A$808,000 in September-quarter customer receipts and positive operating cash flow, but ended the period with only A$14,000 in cash. Its UK and US Tier-1 opportunities advanced towards commercial decisions without yet becoming production contracts.
Victor Sage
Victor Sage
28 Oct 2026
Venari Minerals has funded the next stage of its Red Mountain lithium project after raising $6.1 million, while drilling and permitting advance in Nevada. The company is also testing whether strontium and magnesium can add value beyond lithium carbonate, although commercial recovery remains unproven.
Maxwell Dee
Maxwell Dee
27 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026

Browse the archive

Full archive